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Abstract 
Epithelial membrane protein 3 (EMP3) has recently 
been proposed as a candidate tumor suppressor gene 
(TSG) for some kinds of solid tumors. EMP3 down-
regulation has been explained by its epigenetic 
silencing through aberrant hypermethylation of the 
promoter region.  
EMP3 repression in cancer seems to be an organ-
specific phenomenon, common in neuroblastoma 
and gliomas, relatively common in breast cancer, 
and rare in esophageal squamous cell carcinoma 
(ESCC). Among cancer-derived cell lines, it prevails 
in neuroblastoma, breast cancer and ESCC whereas 
it is rare in glioma, non-small cell lung carcnoma 
(NSCLC), gastric and colon cancer-derived cell 
lines. 
EMP3 expression level is associated with clinical 
prognosis in neuoblastoma, ESCC, NSCLC and 
upper urinary tract urothelial carcinoma. In contrast, 
EMP3 expression may be a novel marker of tumor 
aggressiveness in breast cancer whereas in gliomas, 
EMP3 represssion by aberrant hypermethylation has 
a prognostic signifcance. In both tumor types, 
however, alternative mechanisms to the EMP3 
epigenetic silencing may exist to explain EMP3 
down-regulation.  
Moreover, EMP3 may be involved in the prostate 
cancer suscpetibility. 
Keywords 
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Identity 
Other names: YMP 
HGNC (Hugo): EMP3 
Location: 19q13.33 
Local order 
EMP3 is located centromeric to TMEM143 
(transmembrane protein 143) and telomeric to 
CCDC114 (coiled-coil domain-containing protein 
114). 
Note 
EMP3 is a hydrophobic membrane glycoprotein 
belonging to the PMP22 protein family. It displays a 
high degree of cross-species conservation in its 
nucleotide and protein sequence. 
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Graphical scheme of the human EMP3 gene. Grey boxes correspond to untranslated and black boxes to translated regions 
(all in scale). Arrows indicate the ATG and the stop codons, respectively. 
 
 
DNA/RNA 
Note 
A human EMP3 cDNA was first identified by 
homology screening of databases (Ben-Porath and 
Benvenisty, 1996; Taylor and Suter, 1996). EMP3 
belongs to the peripheral myelin protein 22-kDa 
(PMP22) gene family of small hydrophobic 
membrane glycoproteins (Taylor et al., 1995). It 
includes four closely related members (PMP22, 
EMP1, EMP2 and EMP3), as well as the additional 
and more distant member MP20. The amino acid 
sequence homology with PMP22, EMP1, EMP2 and 
MP20 is 41, 33, 38 and 23%, respectively, with the 
highest homology in the transmembrane domains 
(TMDs). The genomic structure, as well as the 
putative four TMD structure (included a PMP22 
Claudin domain) are highly conserved among family 
members. 
Functionally, the PMP22 gene family may control 
cell proliferation, cell differentiation and cell death. 
Remarkable, mutations in the PMP22 gene are 
responsible for various hereditary peripheral 
neuropathies in both humans and mice (Leal et al., 
2001). 
The human EMP3 gene maps on chromosome 
19q13.33 (Lieher et al., 1999). The homologous 
gene in mouse maps on chromosome 7 (Ben-Porath 
et al., 1998). 
Description 
The genomic size of the human EMP3 gene is of 
5.183 Kb, localized from 48325372 to 48330553. 
The 5'-UTR region contains a CpG island (62 CpG 
dimers) localized around the transcription start site 
(from -13 to +241 bp) (GenBank reference sequence 
NM_001425) (Alaminos et al., 2005). Regulatory 
transcription factor binding sites in the promoter 
region are COUP-TF1, STAT1, Bach2, Rel4, HNF-
4alpha1, E47, AREB6, RORalpha1, HEN1 and 
COUP-TF. 
Transcription 
The gene is composed of five exons, including a non-
coding exon 1, and produces at least nine different 
alternative splicing isoforms. 
Pseudogene 
No known pseudogenes. 
Protein 
EMP3 is a 163-amino acid membrane glycoprotein. 
Description 
EMP3 belongs to the PMP22 protein family and 
shares with its members structural and functional 
homologies. 
Expression 
Promimently expressed in fetal lung, liver and 
kidney, but relatively weakly expressed in both fetal 
and adult brain. In adult, it is ubiquitariously 
expressed in various normal tissues including lung, 
liver, ovary, small intentistine, colon, thymus, 
kidney, pancreas, heart and placenta with the highest 
expression in peripheral blood leukocytes (Taylor 
and Suter, 1996). 
Localisation 
Localised in the cell-membrane and cytoplasm. 
Function 
The function of the EMP3 protein is largely 
unknown but it may be involved in the following 
physiological processes. 
On the basis of its sequence similarity to EMP1, it 
may be involved in the regulation of cell 
proliferation (Bolin et al., 1997). 
The higher expression levels in fetal brain, lung and 
kidney compared to the respective adult counterparts 
suggest a role in the developmental regulation, 
especially in neuronal development (Bolin et al., 
1997). 
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Schematic view of the predicted structure of the multi-pass human EMP3 protein in a lipid bilayer. The Y-shape symbol 
indicates the putative N-linked carbohydrate sites in the first extracellular loop at Asn47 and Asn56 residues. The four 
hydrophobic TMDs (from 4 to 24, 66 to 86, 100 to 120 and 139 to 159 amino acid residues) and the PMP22 Claudin domain 
(from 20 to 156 residues) are shown with respect to the intracellular and extracellular sides of the membrane (Jetten and Suter, 
2000). The molecular weight is of 18.429 kDa. 
 
It may control the regulation of cell growth, 
differentiation and death, since its overexpression 
results in cell blebbing in embryonic kidney cell 
cultures and in the activation of the apoptosis 
pathway (Wilson et al., 2002). 
In peripheral nervous system, it may regulate 
Schwann cell proliferation after injury and cell-cell 
interactions in active myelination (Bolin et al., 
1997). 
It may have possible roles in hematopoietic system 
(Bolin et al., 1997). 
Homology 
Comparative sequence analysis revealed the 
remarkable conservation of the EMP3 primary 
sequence. The EMP3 gene is present in the common 
ancestor of chordates and it is conserved in 
chimpanzee, Rhesus monkey, dog, cow, mouse, rat, 
zebrafish and frog. 
The PMP22 gene family probably evolved as result 
of a chromosome duplication event and divergence 
(Ben-Porath et al., 1998). Paralogs are PMP22, 
EMP1 and EMP2. Seventy-four organisms have 
orthologues with the human EMP3 gene. 
Mutations 
Note 
Neither causative nor functional mutations reported.  
Eighteen human genomic variants from 12 studies 
described, three of which (nsv531627, nsv531628 
and nsv531629, all copy number gains) with 
pathogenic clinical significance since associated to 
global developmental delay and seizure (Miller et 
al., 2010; Kaminsky et al., 2011). 
In mouse, a single nucleotide polymorphism (SNP) 
is responsible for the reciprocal H4 minor 
histocompatibility alloantigens in the MHC-bound 
peptide derived from EMP3 and presented by the 
MHC class I molecule. The C>T nucleotide change 
results in the amino acid substitution from Thr (H4a, 
SGTVYIHL) to Ile (H4b, SGIVYIHL) in the 
minimal antigenic epitope SGIVYIHL (SYL8) 
derived from H4(b) (Yadav et al., 2003; Luedtke et 
al., 2003) 
Germinal 
No germinal mutations described. 
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Somatic 
A total of eight putative somatic mutations reported 
in public databases. Six are missense substitutions 
identified in lung adenocarcinoma (p.Val7Leu), in 
colon adenocarcinoma (p.Val21Met, confirmed 
somatic), in squamous cell lung carcinoma (SCLC) 
(p.A22T, confirmed somatic), in endometrioid 
carcinoma (p.Cys34Arg), in esophageal carcinoma 
(p.Ala65Val) and in large intestine adenocarcinoma 
(p.Met70Val). A p.Asn47Asn synonimous 
substitution detected in colon adenocarcinoma and a 
p.Gly133fs*>31 frameshift deletion in endometrioid 
carcinoma. When not specificied, variants are of 
unknown origin. 
Implicated in 
Neuroblastoma / 
phaeochromocytoma 
By methylation-specific PCR (MS-PCR) and direct 
bisulphate DNA sequencing, EMP3 
hypermethylation is common in both tumor tissue 
(24-68.4%) and neuroblastoma cell lines (33.3%). It 
occurs with concomitant downregulation of EMP3 
protein expression in all clinical samples and in only 
33.3% of neuroblastoma cell lines (Alaminos et al., 
2005; Margetts et al., 2008). EMP3 
hypermethylation is associated with poor survival at 
two-year follow-up and with an high mortality rate 
(Alaminos et al., 2005). 
In contrast, it is a rare event in sporadic (7.1%) and 
adult VHL-associated (6.1%) phaeochromocytomas 
(Margetts et al., 2008). 
Brain tumors / gliomas 
By MS-PCR, EMP3 hypermethylation is an early 
epigenetic event in gliomagenesis. It is common in 
pure (63%) and mixed (70%) oligodendroglial 
tumors in comparison to astrocytic ones (18%). It 
prevails in grade II (71.4%) upon grade III (44.7%) 
gliomas, and in secondary (89%) upon primary 
GBMs (17%) (Alaminos et al., 2005; Li et al., 2007; 
Kunitz et al., 2007; Mellai et al., 2013). Not found in 
GBM cell lines (Ernst et al., 2009).  
Aberrant hypermethylation correlates with reduced 
mRNA expression and lack of EMP3 protein 
expression. It is strongly associated with 
IDH1/IDH2 somatic mutations in astrocytic and 
oligodendroglial tumors and inversely correlated 
with EGFR gene amplification. In 
oligodendrogliomas, it is also associated with loss of 
the 19q13.3 locus and with total 1p/19q co-deletion 
(Tews et al., 2006; Mellai et al., 2013), with 
prognostic significance on patient overall survival 
(Kunitz et al., 2007; Mellai et al., 2013). 
The EMP3 gene belongs to the glioma CpG island 
methylator phenotype (G-CIMP) (Noushmehr et al., 
2010), that identifies a distinct molecular glioma 
subclass, prevalent in low-grade tumors and 
associated with IDH1/2 mutations and with 
improved patient survival (Laffaire et al., 2011). 
No tumor-specific mutations identified on 132 
glioma patients, except for the SNPs rs4893 
(p.Ile125Val, exon 5) and rs11671746 (3'-UTR) in 
four patients (Kunitz et al., 2007). 
Esophageal squamous cell 
carcinoma (ESCC) 
By MS-PCR, EMP3 hpermethylation is rare in tumor 
tissue (6%) but frequent in ESCC cell lines (75%), 
with an inverse correlation with mRNA expression 
levels (Fumoto et al., 2009a). Low EMP3 expression 
is associated with poor prognosis after recurrence, 
suggesting that EMP3 inactivation may confer an 
advantage for tumor growth only at late stage of 
disease. 
Breast cancer 
By RT-PCR, EMP3 mRNA expression is 
significantly higher in primary tumors than in 
normal breast tissue.  
It correlates with the histologic grade III, lymph 
node metastatis and Her-2 expression in human 
mammary luminal epithelial cells (Mackey et al., 
2003 ; Zhou et al., 2009). It may be a novel marker 
of tumor aggressiveness (Zhou et al., 2009).  
By MS-PCR, EMP3 hypermethylation occurs 
occasionally in primary tumor tissue (36.5%) 
without association with mRNA expression levels. 
In breast cancer cell lines, EMP3 mRNA is 
frequently repressed in both invasive (70%) and non-
invasive phenotype (75%).  
Promoter hypermethylation may explain mRNA 
repression in almost all the non-invasive phenotype 
and in only a part of the invasive phenotype 
(Evtimova et al., 2003). 
Non-small cell lung cancer (NSCLC) 
By Western blotting, EMP3 expression in tumor 
tissue is signifcantly lower than in normal lung 
tissue, correlates with the p-TNM stage and 
negatively with the proliferation index Ki-67. EMP3 
may be a TSG at late stage of disease and a potential 
marker of prognosis in lung patients (Xue et al., 
2013). 
In lung cell lines, EMP3 is repressed with partial 
CpG hypermethylation in 11.1% of cases (Fumoto et 
al, 2009a). 
Upper urinary tract urothelial 
carcinoma 
At mRNA and protein level, EMP3 overexpression 
promotes in vitro tumor cell proliferation and 
migration by activation of the ErbB2-PI3K-AKT 
pathway.  
It suppresses cell adhesion. EMP3 and ErbB2 co-
espression is the most important marker of 
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progression-free and metastasis-free patient survival 
(Wang et al., 2013). 
Prostate cancer 
By a case-control study in 275 multiplex sibships on 
candidate genes and genomic regions with linkage to 
tumor suscpetibility and/or aggressiveness, the 
rs4893 variant displays a highly significant 
association, confirmed in a age-matched subsample. 
The EMP3 association, together with HPN: gene 
(19q11-q13.2), suggests the involvement of multiple 
genes within this genomic region in the prostate 
cancer susceptibility. The rs4893 allelic variant is 
significantly more frequent in prostate cancer 
patients compared to controls (Burmester et al., 
2004). 
Other malignancies 
By RT-PCR, EMP3 displays high mRNA expression 
in gastric and colon cancer-derived cell lines 
(Fumoto et al., 2009b). 
Keratoconus (KC) 
By RT-PCR, EMP3 is significantly upregulated (2.5-
fold) in keratoconus patients compared to a reference 
control group (Nielsen et al., 2005). EMP3 may have 
a potential role in the epithelial changes of the 
disease in agreement with the finding of blebs on the 
surface of KC corneas (Pfister and Burstein, 1977). 
Breakpoints 
Unknown fusion proteins.. 
To be noted 
No genetic variants in the regulatory or coding 
regions responsible for EMP3 repression in cancer-
derived cell lines without EMP3 hypermethylation 
or for EMP3 overexpression in other cancer-derived 
cell lines. An exception is the finding of the rs4893 
allelic variant in the Caucasian A549 NSCLC cell 
line (Fumoto et al., 2009a) within a panel of 45 
representative cancer cell lines. A Japanese- or 
Asian-population specific haplotype of three SNPs 
(rs8102349, rs8355 and rs11665) in non-coding 
regions is reported without association with the 
EMP3 expression levels (Fumoto et al., 2009a). 
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